Used in the context of the Marshall ProtocolA curative medical treatment for chronic inflammatory disease. Based on the Marshall Pathogenesis. (MP), a therapeutic probeA brief trial of the Marshall Protocol to see if it will generate an immunopathological response. The "gold standard" for testing whether a patient is a good candidate for the MP. refers to a brief trial of the MP, in which patients take regular doses of olmesartan (Benicar)Medication taken regularly by patients on the Marshall Protocol for its ability to activate the Vitamin D Receptor. with pulsed, low doses of antibiotics and restrict consumption of vitamin D. The presence of a positive treatment response is taken as an indication that a patient is sick with Th1 diseaseAny of the chronic inflammatory diseases caused by bacterial pathogens. and that the MP is a treatment option for that disease. Although there are other factors and variables, which can strongly suggest the presence of Th1 disease, the therapeutic probe is currently the best method for determining if the MP may be suitable for a patient.
In the context of the therapeutic probe, there are at least three responses or types of responses which indicate that continued treatment with the MP is warranted:
- photosensitivityAbnormal sensitivity to sunlight and bright lights. Also referred to as "sun flare" or "light flare." – Even if patients have never been light sensitive before, they may find lights to be too bright for comfort. Patients are cautioned that photosensitivity (and other symptoms) can occur in response to a withdrawal of typical levels of light exposure, even before the use of olmesartanMedication taken regularly by patients on the Marshall Protocol for its ability to activate the Vitamin D Receptor. Also known by the trade name Benicar. is commenced.
- noticeable spike in symptoms – An activator of the innate immune responseThe body's first line of defense against intracellular and other pathogens. According to the Marshall Pathogenesis the innate immune system becomes disabled as patients develop chronic disease., Benicar works with minocycline to kill pathogenic bacteria. The effect of a strengthened immune system response is called immunopathologyA temporary increase in disease symptoms experienced by Marshall Protocol patients that results from the release of cytokines and endotoxins as disease-causing bacteria are killed.. Immunopathology feels bad because the killing of bacteria generates cytokinesAny of various protein molecules secreted by cells of the immune system that serve to regulate the immune system., endotoxins, and nitric oxide.
- noticeable relief in symptoms – As an ARBA drug which is an angiotensin receptor blocker. One of the ARBs is olmesartan (Benicar). Not all ARBs activate the Vitamin D Receptor., Benicar has profound anti-inflammatory effects, which manifest in a reduction in pain, fatigue, and other symptoms of Th1 disease.
Symptoms which wax and wane in tandem with the every-other-day administration of antibiotics are an especially strong indication of Th1 disease.
It is expected that the way a patient responds to the MP will change over time.